-
Norovirus NINJ1 Co-option Enables Selective NS1 Secretion
2026-09-15
Song and colleagues show that murine norovirus co-opts the membrane-rupture protein NINJ1 to release the viral NS1 protein through an unconventional secretion pathway. By combining CRISPR screening, localization and interaction studies, NS1 mutagenesis, and mouse infection experiments, the study connects caspase-3 activity and NINJ1 to mucosal norovirus pathogenesis.
-
1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine Control
2026-09-15
PP 3 is a practical negative control for PP 2-based Src kinase experiments, helping separate Src-dependent biology from vehicle, scaffold, and assay effects. Its value is especially clear in vascular ROS studies, where pathway-selective controls can distinguish kinase signaling from L-type calcium-channel mechanisms.
-
ML216 BLM Helicase Inhibitor: Research Workflows
2026-09-14
ML216 is a selective research probe for testing how BLM-dependent DNA unwinding influences repair, genome stability, and tumor-cell response to chemotherapy. This guide connects biochemical inhibition with cell proliferation, sister chromatid exchange, and carefully controlled RecQ-helicase studies, including the WRN–MSI colorectal cancer context.
-
Sulfo-NHS-LC-Biotin: Protocol and QC Guide
2026-09-14
Sulfo-NHS-LC-Biotin provides water-compatible, irreversible biotin labeling of accessible primary amines on proteins, peptides, and intact cell surfaces. It is suitable for stable cell surface protein biotinylation and streptavidin-based capture, but not for intracellular labeling of intact cells or reversible biotinylation workflows.
-
Intracellular Photocatalytic NADH Oxidation in Cancer
2026-09-13
The 2025 JACS Perspective defines intracellular NADH/NAD(P)H oxidation as a catalytic mechanism for photocatalytic cancer therapy, linking metal-based photoredox chemistry to disruption of cancer-cell redox metabolism. It evaluates Ir(III), Ru(II), Re(I), and Os(II) photocatalysts, while identifying uptake, selectivity, catalyst stability, and clinical translation as major challenges.
-
β-Elemene: Reproducible Cell Assay Workflows
2026-09-12
This scenario-based guide explains how β-Elemene, SKU C5505, can support reproducible viability, adipogenesis, apoptosis, and signaling experiments. It combines published 3T3-L1 workflow parameters with practical guidance on dosing, solvent controls, interpretation, and product selection.
-
Aminopeptidase Selectivity in ACE Inhibitor Studies
2026-09-12
The reference study re-evaluated inhibitor selectivity across three porcine kidney cell-surface zinc aminopeptidases: AP-A, AP-N, and AP-W. Its side-by-side comparison showed that several commonly used metallopeptidase inhibitors are not interchangeable, while selected sulfhydryl ACE inhibitors can inhibit AP-W without substantially affecting AP-A or AP-N.
-
Omeprazole (A2845): Practical Acid Secretion Workflow
2026-09-11
Omeprazole (A2845) provides a defined H+,K+-ATPase inhibitor for controlled gastric acid secretion research, antiulcer activity studies, and related assay development. It is intended for scientific laboratory use only; its insolubility in water and ethanol, solution stability limits, and lack of directly matched paper evidence require careful vehicle control, fresh-solution handling, and context-specific interpretation.
-
Early Life Adversity, Oxytocin, and Innate Defense
2026-09-11
Tan et al. report that social deprivation during early postnatal development weakens looming-evoked innate defensive behavior in mice through disrupted oxytocin signaling in the superior colliculus. The study connects an early environmental stressor to a defined midbrain circuit and shows that intranasal oxytocin can ameliorate the behavioral deficit, while also identifying important limits for translation to human psychopathology.
-
(S)-(+)-Dimethindene maleate Lab Guide
2026-09-10
This guide explains how to use (S)-(+)-Dimethindene maleate as a research antagonist when M2 muscarinic activity must be interpreted alongside its histamine H1 activity. It supports controlled receptor, autonomic, cardiovascular, and respiratory assays, but it should not be used for diagnosis, treatment, or clinical decision-making.
-
Oxaliplatin: DNA Damage Meets Tumor Immunity
2026-09-10
Oxaliplatin is a platinum-based chemotherapeutic agent best understood not only through DNA adduct formation, but also through the assay context surrounding tumor growth, apoptosis, and immune exclusion. This article translates Wnt–β-catenin research into a practical framework for designing mechanistically resolved Oxaliplatin experiments.
-
Patient-Derived Gastric Cancer Assembloids
2026-09-09
Shapira-Netanelov and colleagues developed a patient-derived gastric cancer assembloid model that combines matched tumor organoids with tumor-derived stromal subpopulations. The study shows that stromal composition alters gene expression and drug sensitivity, creating a more physiologically informative platform for resistance studies and personalized treatment design.
-
HotStart™ Universal 2X Green qPCR Master Mix for NSCLC
2026-09-09
HotStart Universal 2X Green qPCR Master Mix supports rigorous NSCLC pathway validation by connecting SPI1/miR-616-5p biology with reproducible real-time PCR gene expression analysis. This article explains assay design, miRNA-specific considerations, melt-curve interpretation, and how to translate mechanistic cancer findings into defensible qPCR data.
-
Synthetic OLIG2 mRNA Drives Oligodendrocyte Differentiation
2026-09-08
Xu and colleagues developed a transgene-free strategy that uses repeated delivery of modified OLIG2 messenger RNA to convert human induced pluripotent stem cells into oligodendrocyte progenitor cells and mature oligodendrocytes. The study links a phosphorylation-resistant OLIG2 variant with a short differentiation protocol, functional maturation in vitro, and remyelination activity in vivo.
-
FAK Inhibitor 14 Cancer Research Workflows
2026-09-08
FAK Inhibitor 14 provides a practical pharmacological tool for testing whether FAK/Src signaling drives migration, EMT, and matrix remodeling in cholesterol-adapted cancer models. This workflow pairs target engagement, viability controls, and migration assays to distinguish pathway dependence from nonspecific growth inhibition.